All Oncology News

Treatment with neoadjuvant nivolumab led to encouraging 5-year recurrence-free survival and overall survival rates compared with historical outcomes in patients with non–small cell lung cancer who underwent surgical resection.

Cedars-Sinai investigators verify that rates are trending up for both sexes; younger women and Black women see steepest increase.

Advances in the development of bispecific antibodies have demonstrated response rates close to or surpassing those of other agents in development, offering investigators an avenue to pursue phase 3 studies such as EPCORE DLBCL-1 to challenge standard of care with the CD3 × CD20 agent, epcoritamab in diffuse large B-cell lymphoma.

François-Clément Bidard, MD, PhD, discusses how elacestrant fits into the treatment paradigm for postmenopausal patients with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

The FDA has issued a refusal to file letter for a new drug application seeking the approval of HyBryte, Soligenix’s synthetic hypericin, for use in patients with early-stage cutaneous T-cell lymphoma.

Treatment with brexucabtagene autoleucel in the standard-of-care relapsed/refractory mantle cell lymphoma setting provided an efficacy and safety profile consistent with data reported in the phase 2 ZUMA-2 trial.

Dario R. Roque, MD, discusses incorporating PARP inhibitors into practice for patients with homologous recombination deficient ovarian cancer, the role of PARP inhibitors for patients with homologous recombination–proficient ovarian cancer and the expanding investigation of mirvetuximab soravtansine in ovarian cancer.

The National Comprehensive Cancer Network breast cancer guidelines issued February 7, 2003, added the MammaPrint UltraLow Risk gene expression assay to its list of recommended assays for consideration of adjuvant systemic therapy.

Researchers at Fox Chase Cancer Center were recently awarded a $550,000 grant from Stand Up To Cancer (SU2C) to fund a new project, “Accelerating and Diversifying Access to Clinical Trials.”

The FDA has granted regenerative medicine advanced therapy and fast track designations to equecabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma.

A renewed focus on dismantling the barriers and closing gaps in care will aid in the mission to drive down the rate of cancer mortality and incidence across disease states.

Mariana Chavez-MacGregor, MD, MSC, discussed key efficacy and safety data from the SWOG 1207 trial of adjuvant everolimus in postmenopausal patients with high-risk, hormone receptor–positive breast cancer.

Topline results from the phase 1 European MB-105 clinical trial showed that new safety results for annamycin, a next-generation anthracycline, are in keeping with previous findings for patients with relapsed/refractory acute myeloid leukemia.

The combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cell lymphoma, according to preliminary findings from the phase 2b VITALIZE trial.

Thomas J. George, MD, FACP, highlights the long-term data from the NRG-GI002 trial, the next steps for exploring subsets of patients who may benefit from the addition of pembrolizumab or veliparib to total neoadjuvant therapy, and what the use of total neoadjuvant therapy has meant for patients with stage II/III locally advanced rectal cancer.

Findings from the MASTER trial in multiple myeloma could help shape how future treatment decisions are approached for fit, transplant-eligible patients.

Michael C. Haffner, MD, PhD, explains the genomic differences between prostate adenocarcinoma of the prostate and prostatic basal cell carcinoma, an extremely rare disease.

Kyle A. Blum, MD, MS, says that results from a study of patients renal medullary carcinoma suggest that with CA-125, an established biomarker for ovarian cancer, may play a similar role in this rare disease.

Kyle A. Blum, MD, MS, says that patients with renal medullary carcinoma have poor prognosis, but anecdotal evidence suggests that survival outcomes may be improving.

The Barbara Ann Karmanos Cancer Institute is now seeing patients at the new Karmanos Cancer Institute – Roseville.

Kyle A. Blum, MD, MS, discusses how few physicians have experience with renal medullary carcinoma, and the disease often presents with nonspecific symptoms.

Kyle A. Blum, MD, MS, explains how renal medullary cancer, like most rare cancers, can be difficult to study. However, there are several ongoing studies that include this patient population.

Adding trilaciclib to FOLFOXIRI and bevacizumab led to statistically significant reductions in instances of severe neutropenia during induction and duration of severe neutropenia in cycles 1 to 4. However, the combination failed to improve antitumor activity vs placebo plus FOLFOXIRI/bevacizumab in patients with metastatic colorectal cancer.

Research groups in the United States and Europe are seeking to build the knowledge base about invasive lobular carcinoma in hopes that therapy can be tailored for patients with this diagnosis.

James Harding, MD, highlighted current and emerging areas of research in biliary tract cancer, including key contributions from TOPAZ-1 and the phase 3 SWOG 1815 trial, the development of immunotherapy and chemotherapy combinations, and continued efforts to utilize personalized medicine in clinical practice.

Rohit Kumar, MD, discusses the benefits of TKI/immunotherapy doublets in renal cell carcinoma, unmet needs regarding future research with triplet therapies in the frontline setting, and how hypoxia inducible factor inhibitors may play a role in the treatment of patients who have progressed on prior TKI/immunotherapy combinations.

Matthew Brunner, MD, discusses how key patient factors, the use of advanced imaging modalities, and the relationship between community and academic centers influence treatment approaches in relapsed/refractory multiple myeloma.

In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted in substantially better responses than standard treatments.

The FDA has placed a partial clinical hold on the phase 1/2 VELA trial due to visual adverse effects observed in select patients who received the investigational treatment BLU-222.

The National Comprehensive Cancer Network has partnered with the American Cancer Society Cancer Action Network and the National Minority Quality Forum to launch the new Health Equity Report Card pilot program to address structural and interpersonal bigotry that results in disparities in cancer care and outcomes.